Synergy Pharmaceuticals Closes Enrollment for Phase 2b Plecanatide Trial in Patients with IBS-C
December 24, 2013 at 06:07 AM EST
- Synergy Pharmaceuticals. (NASDAQ: SGYP ) today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C). The clinical
